Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer.
10.1007/s11655-024-4116-7
- Author:
Ke CHANG
1
;
Li-Fei ZHU
1
;
Ting-Ting WU
1
;
Si-Qi ZHANG
1
;
Zi-Cheng YU
2
Author Information
1. Department of Pharmacy, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China.
2. Department of Pharmacy, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. yuzicheng666@foxmail.com.
- Publication Type:Journal Article
- Keywords:
in vitro experiments;
Chinese medicine;
molecular docking;
network pharmacology;
non-small cell lung cancer;
oridonin
- MeSH:
Diterpenes, Kaurane/chemistry*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Humans;
Network Pharmacology;
Lung Neoplasms/pathology*;
Cell Proliferation/drug effects*;
Apoptosis/drug effects*;
Molecular Docking Simulation;
Protein Interaction Maps/drug effects*;
Cell Line, Tumor;
Signal Transduction/drug effects*;
Gene Expression Regulation, Neoplastic/drug effects*;
Reproducibility of Results;
Gene Ontology
- From:
Chinese journal of integrative medicine
2025;31(4):347-356
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the key target molecules and potential mechanisms of oridonin against non-small cell lung cancer (NSCLC).
METHODS:The target molecules of oridonin were retrieved from SEA, STITCH, SuperPred and TargetPred databases; target genes associated with the treatment of NSCLC were retrieved from GeneCards, DisGeNET and TTD databases. Then, the overlapping target molecules between the drug and the disease were identified. The protein-protein interaction (PPI) was constructed using the STRING database according to overlapping targets, and Cytoscape was used to screen for key targets. Molecular docking verification were performed using AutoDockTools and PyMOL software. Using the DAVID database, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted. The impact of oridonin on the proliferation and apoptosis of NSCLC cells was assessed using cell counting kit-8, cell proliferation EdU image kit, and Annexin V-FITC/PI apoptosis kit respectively. Moreover, real-time quantitative PCR and Western blot were used to verify the potential mechanisms.
RESULTS:Fifty-six target molecules and 12 key target molecules of oridonin involved in NSCLC treatment were identified, including tumor protein 53 (TP53), Caspase-3, signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinase kinase 8 (MAPK8), and mammalian target of rapamycin (mTOR). Molecular docking showed that oridonin and its key target molecules bind spontaneously. GO and KEGG enrichment analyses revealed cancer, apoptosis, phosphoinositide-3 kinase/protein kinase B (PI3K/Akt), and other signaling pathways. In vitro experiments showed that oridonin inhibited the proliferation, induced apoptosis, downregulated the expression of Bcl-2 and Akt, and upregulated the expression of Caspase-3.
CONCLUSION:Oridonin can act on multiple targets and pathways to exert its inhibitory effects on NSCLC, and its mechanism may be related to upregulating the expression of Caspase-3 and downregulating the expressions of Akt and Bcl-2.
